François Bertucci

Responsable d'équipe PU-PH / HDR
Voir les publications Voir le mail Tel : 47 79
Equipe
Publications
Jun 2020 Nature structural & molecular biology

Publisher Correction: SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.

Takedachi A, Despras E, Scaglione S, Guérois R, Guervilly JH, Blin M, Audebert S, Camoin L, Hasanova Z, Schertzer M, Guille A, Churikov D, Callebaut I, Naim V, Chaffanet M, Borg JP, Bertucci F, Revy P, Birnbaum D, Londoño-Vallejo A, Kannouche PL, Gaillard PHL

May 2020 Nature structural & molecular biology

SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations.

Takedachi A, Despras E, Scaglione S, Guérois R, Guervilly JH, Blin M, Audebert S, Camoin L, Hasanova Z, Schertzer M, Guille A, Churikov D, Callebaut I, Naim V, Chaffanet M, Borg JP, Bertucci F, Revy P, Birnbaum D, Londoño-Vallejo A, Kannouche PL, Gaillard PHL

May 2016 Developmental cell

PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2.

Daulat AM, Bertucci F, Audebert S, Sergé A, Finetti P, Josselin E, Castellano R, Birnbaum D, Angers S, Borg JP

Sep 2022 Journal of cell science

The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins.

Daulat AM, Wagner MS, Audebert S, Kowalczewska M, Ariey-Bonnet J, Finetti P, Bertucci F, Camoin L, Borg JP

Aug 2022 Science signaling

CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness.

Nigri J, Leca J, Tubiana SS, Finetti P, Guillaumond F, Martinez S, Lac S, Iovanna JL, Audebert S, Camoin L, Vasseur S, Bertucci F, Tomasini R

Aug 2022 Molecular therapy : the journal of the American Society of Gene Therapy

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, Baudelet E, Hamimed M, Barbolosi D, Finetti P, Bastide C, Fazli L, Gleave M, Bertucci F, Taïeb D, Rocchi P

Mar 2022 The EMBO journal

Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.

Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S

Jul 2021 Biomedicines

Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment.

Nguyen DT, Le TK, Paris C, Cherif C, Audebert S, Udu-Ituma SO, Benizri S, Barthélémy P, Bertucci F, Taïeb D, Rocchi P

Jan 2021 Cancers

Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2 γδ T Cell Alterations with Lymph Node Invasion.

Fattori S, Gorvel L, Granjeaud S, Rochigneux P, Rouvière MS, Ben Amara A, Boucherit N, Paul M, Dauplat MM, Thomassin-Piana J, Paciencia-Gros M, Avenin M, Pakradouni J, Barrou J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Goncalves A, Tarpin C, Nunès JA, Devillier R, Chretien AS, Olive D

Sep 2020 Cancers

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?

Aulas A, Finetti P, Lyons SM, Bertucci F, Birnbaum D, Acquaviva C, Mamessier E

Mar 2020 Molecular oncology

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S

Feb 2020 Breast cancer research and treatment

Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.

Rypens C, Marsan M, Van Berckelaer C, Billiet C, Melis K, Lopez SP, van Dam P, Devi GR, Finetti P, Ueno NT, Bertucci F, Dirix P, Neven P, Vermeulen P, Dirix L, Van Laere SJ

Feb 2020 European journal of cancer (Oxford, England : 1990)

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.

Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Brodowicz T, Decoupigny E, Vanseymortier M, Laroche L, Taieb S, Le Deley MC, Blay JY

Voir toutes les publications